Modulari-T Biosciences is a Montreal-based biotech working on what may be one of the most significant advances in cell therapy in decades. The team has built the first second generation in vivo CAR-T system, one designed to work with the immune system rather than against it, and has already proven the technology across nearly twenty different target types, including cancers that earlier generations of CAR-T simply could not reach.

In this episode, Jim Wilson speaks with CEO Tanya Borsuk about a company she never expected to join. After years at Celgene, which became Bristol-Myers Squibb, watching CAR-T hit its limits, Tanya swore she would never work in the field again. Then she saw Modulari-T's data. She explains what makes the technology different, why toxicity and accessibility have long held cell therapy back, and how this Canadian science could open the door to treating not just cancer but autoimmune, inflammatory, and neurological diseases.

Tanya also reflects on the realities of building a young biotech in a difficult market, and why she believes the most important lesson any entrepreneur can learn is to not be afraid to fail.

Based in Calgary, Alberta, Providence Therapeutics is a Canadian mRNA company focused on personalized cancer vaccines. During the pandemic, Brad Sorenson and his team developed a COVID vaccine that went head to head against Pfizer in clinical trials and held its own, yet almost no one in Canada ever heard about it.

In this episode, host Jim Wilson speaks with founder and CEO Brad Sorenson about a journey that is as personal as it is professional. In 2013, Brad's 13-year-old son Adam was diagnosed with glioblastoma and given a year to live. Thirteen years later, Adam is still here, and Brad walks through the extraordinary series of events that shaped both his son's survival and the company he built.

It is also a candid conversation about the realities of drug development in Canada and Brad's passionate call for the country to give patients the right to fight for their lives through compassionate access.

Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's.

Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether.

In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University.

Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients.

Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.